Oridonin: Natural NLRP3 Inhibitor from Traditional Medicine¶

Oridonin is an ent-kaurane diterpenoid compound isolated from Rabdosia rubescens, a plant used in traditional Chinese medicine. It is a specific, covalent NLRP3 inflammasome inhibitor that targets the exact same binding site used by the pharmaceutical NLRP3 inhibitor MCC950, achieving comparable potency through a natural product scaffold.

Species-gap caveat (methodological standard, 2026-04-23): Rodent cellular IC50 values for NLRP3 inhibitors routinely diverge from human cellular IC50 by up to 3 orders of magnitude. Example: dapansutrile IC50 = 1 nM in mouse J774A.1 cells vs. 1,000 nM (1 μM) in human MDM cells under LPS+nigericin stimulation (ChEMBL v34, 2026-04-23). Every rodent-derived IC50 in this document should be read with that translation uncertainty in mind — mouse efficacy is still the best preclinical gout predictor we have, but dose translation requires a species-bridging measurement (e.g., a human THP-1 IC50) before making dosing claims. (source: chembl-cross-check.md)

Mechanism: Covalent NLRP3 Inhibition at NACHT Domain Cys279¶

The Binding Target¶

Oridonin covalently and irreversibly modifies cysteine 279 (Cys279) in the NACHT domain of NLRP3 protein. This domain contains the nucleotide-binding pocket essential for NLRP3 conformational changes required for inflammasome assembly.

By forming a covalent bond at this site, oridonin prevents the NLRP3-NEK7 interaction — a critical step in inflammasome platform formation. This is the same mechanism targeted by MCC950 (a pharmacological NLRP3 inhibitor), but through a different chemical approach.

(Source: nlrp3-exploit-map.md) — "Oridonin, an ent-kaurane diterpenoid from the Chinese herb Rabdosia rubescens, covalently and specifically modifies NLRP3 at cysteine 279. This is the same domain that MCC950 targets — the NACHT domain. By forming an irreversible covalent bond, oridonin blocks the NLRP3-NEK7 interaction that's essential for inflammasome assembly."

The Chemistry: Michael Addition¶

Oridonin's mechanism is a Michael addition — a nucleophilic attack by the thiol group of Cys279 on the α,β-unsaturated carbonyl in oridonin's molecular structure. This is the same type of covalent modification used by other natural NLRP3 inhibitors and by some pharmaceutical compounds.

Potency & Specificity¶

Active Concentration¶

Oridonin exhibits dose-dependent inhibition of NLRP3 in cell culture: - Caspase-1 cleavage: reduced dose-dependently - IL-1β secretion: suppressed - Pyroptotic cell death: prevented

Curated human NLRP3 IC50 (ChEMBL v34, queried 2026-04-23): 5,180 nM (5.18 μM) in human THP-1 macrophages under LPS/ATP stimulation (Eur J Med Chem 2023, ChEMBL ID CHEMBL1164920, pChEMBL = 5.29). This is the only direct human NLRP3 bioactivity for oridonin in the ChEMBL database — which is stricter than review-literature citations because it requires a curated binding/inhibition assay, not a downstream IL-1β readout. (In Vitro; source: nlrp3-inhibitor-screen.md)

Legacy citation (0.5–2 μM): The commonly repeated "0.5–2 μM" figure — including earlier versions of this page — derives from the 2018 Nature Communications paper (Cys279 covalent binding kinetics), which reported cell-free and mouse-derived assays. It does not translate 1:1 to the curated human-cell IC50 above. Treat the two numbers as complementary: 0.5–2 μM for covalent-binding-kinetic potency (cell-free/mouse), 5.18 μM for human cellular IC50. (source: nlrp3-inhibitor-screen.md)

These concentrations are physiologically achievable with oral supplementation, but the potency gap versus pharmaceutical benchmarks is larger than older wiki framing implied — dapansutrile (also 1 μM human cellular IC50) is in the same order of magnitude as oridonin in human cells, not orders of magnitude more potent. MCC950's 7.5 nM figure is from the original Coll et al. 2015 J Biol Chem paper (cell-free NACHT Walker B) and is not directly comparable to cellular IC50 without a head-to-head assay.

NLRP3-Specific¶

Critically, oridonin does not affect other inflammasome types — specifically NLRC4 or AIM2 inflammasomes, which operate through different mechanisms. This selectivity is important for safety; non-selective inflammasome inhibition could impair other critical immune responses.

(Source: nlrp3-exploit-map.md) — "Published in Nature Communications (2018): oridonin exhibits dose-dependent inhibition of caspase-1 cleavage, IL-1β secretion, and pyroptotic cell death at concentrations of 0.5–2 µM. It's NLRP3-specific — doesn't affect NLRC4 or AIM2 inflammasomes."

Multi-Pathway Inhibition¶

Beyond direct NLRP3 inhibition, oridonin activates secondary anti-inflammatory pathways:

Nrf2 Activation (Signal 1 / Chokepoint 1)¶

Oridonin activates Nrf2 (nuclear factor erythroid 2-related factor 2), the master regulator of cellular antioxidant defense. This suppresses NF-κB-driven transcription of inflammatory genes.

NF-κB Suppression (Chokepoint 1)¶

Direct suppression of NF-κB pathway in addition to Nrf2 effects.

(Source: nlrp3-exploit-map.md) — "The dual hit: Beyond NLRP3, oridonin also activates Nrf2 and suppresses NF-κB independently. So it hits CP1 AND CP2 through different mechanisms."

This multi-target property makes oridonin more potent than a single-mechanism inhibitor — it attacks both the priming step (NF-κB) and the activation step (NLRP3 direct inhibition).

Evidence Level: Published Mechanism in Nature Communications¶

The peer-reviewed evidence for oridonin's NLRP3 inhibition is strong:

Primary mechanism: 2018 Nature Communications study on covalent NLRP3-Cys279 modification
Analog development: 2025 research on more potent oridonin derivatives
Gout-specific studies: ✗ None published
Human clinical trials: ✗ None

The mechanism is well-established in cell culture and animal models, but clinical translation to gout has not occurred.

(Source: nlrp3-exploit-map.md) — "Published in Nature Communications (2018): oridonin exhibits dose-dependent inhibition of caspase-1 cleavage, IL-1β secretion, and pyroptotic cell death at concentrations of 0.5–2 µM." (As noted above, this figure is from the original covalent-binding kinetic assays and does not equal the curated human THP-1 cellular IC50 of 5.18 μM — Eur J Med Chem 2023, ChEMBL entry.)

Traditional Medicine Provenance¶

Rabdosia rubescens Usage¶

Rabdosia rubescens (also called Isodon rubescens) is a plant used in traditional Chinese medicine for inflammatory conditions, clearing heat, and removing toxins (冬凌草 Dong Ling Cao — "heat-clearing detoxification" category in TCM materia medica). The plant has been used for centuries in Asian herbal medicine, though oridonin specifically was only isolated and characterized in modern times.

Oridonin is one of several TCM-lineage compounds in the Open Enzyme stack. The broader methodology for applying modern scientific rigor to TCM materia medica — including chokepoint mapping, ChEMBL cross-check, bioavailability-honest framing, and formula decomposition — is formalized in tcm-modern-rigor-intersection.md. Oridonin is explicitly listed there as a TCM-lineage compound with an existing wiki page. (source: tcm-modern-rigor-intersection.md)

Modern Extraction & Standardization¶

Commercial preparations typically contain: - Crude Rabdosia extracts (standardized to oridonin content by HPLC) - Isolated oridonin powder (higher concentration, more expensive) - Combination formulas blending Rabdosia with other anti-inflammatory herbs

Bioavailability Considerations¶

Natural plant extracts vary significantly in bioavailability. Oridonin-specific extracts are more consistent than whole-plant preparations. Oral supplementation of isolated oridonin or standardized extracts (50–200 mg/day) achieves active serum concentrations.

Comparison: Oridonin vs. Pharmaceutical NLRP3 Inhibitors¶

Compound	Target	Mechanism	Curated human NLRP3 IC50 (ChEMBL v34)	Status	Cost	Safety
Oridonin	NLRP3 Cys279	Covalent (natural)	5.18 μM (THP-1, Eur J Med Chem 2023)	Available now	~$20–40/month	Good (traditional use)
MCC950	NLRP3 Walker B	Non-covalent (pharma)	7.5 nM (cell-free, Coll 2015 — not in ChEMBL by common synonyms)	Discontinued (Phase 1 hepatotoxicity)	NA	Hepatotoxic
Dapansutrile	NLRP3 (general)	Direct inhibitor	1.0 μM human MDM / 1.0 nM mouse J774A.1 (1000× species gap)	Phase 2a in gout published 2020; no Phase 2b/3 registered as of 2026-04	Unknown	Good (Phase 2 safety)
Tranilast	NLRP3 NACHT	Non-covalent (pharma)	Zero direct human NLRP3 bioactivities in ChEMBL (2017 EMBO Mol Med NACHT-binding claim rests on non-ChEMBL assays)	Approved (Japan/Korea)	~$30–50/month	Good (decades of use)

(IC50 values above reflect ChEMBL v34 curated cross-check, 2026-04-23. source: nlrp3-inhibitor-screen.md)

Key observation: Oridonin is a covalent NLRP3 inhibitor like MCC950, but unlike MCC950 it has not shown hepatotoxicity. It's available immediately, costs far less than clinical-stage drugs, and has the advantage of traditional use history (though this is not the same as modern clinical trial validation).

Revised potency framing (2026-04-23): When comparing cellular IC50 in human cells rather than cell-free NACHT-binding kinetics, oridonin (5.18 μM) and dapansutrile (1.0 μM) are within ~5× of each other. Dapansutrile's mouse cellular IC50 of 1 nM is 1,000× more potent than its own human cellular IC50 — a major species gap that reframes how we should interpret rodent NLRP3-inhibitor preclinical data generally. Oridonin's gap between cell-free covalent-binding kinetics (~0.5–2 μM) and human cellular IC50 (5.18 μM) is small by comparison. (source: nlrp3-inhibitor-screen.md)

Derivative Development¶

Recent research (2025) has focused on synthetic analogs of oridonin that achieve even higher NLRP3 potency while maintaining the safety profile:

(Source: nlrp3-exploit-map.md) — "recent 2025 research on oridonin analogs shows you can engineer even more potent derivatives."

These next-generation compounds could combine oridonin's natural product scaffold with enhanced pharmaceutical properties.

Contraindications, Drug Interactions, and Dose-Dependent Risk¶

Standardized safety profile (source: supplements-stack.md, 2026-04-26): The following section consolidates contraindications, drug interactions, and dose-dependent risk from the supplements catalog.

Contraindications: - Pregnancy (insufficient data; covalent-binding mechanism warrants caution) - Pediatric use (insufficient data) - Active hepatic disease (some Rabdosia preparations have hepatotoxicity case reports at high TCM-formula doses) - Combination with other covalent-mechanism drugs without spacing (theoretical concern)

Drug interactions: - CYP3A4 substrates: preliminary in vitro data suggests modest CYP3A4 inhibition by oridonin — relevant for tacrolimus, cyclosporine, simvastatin, some calcium channel blockers, and direct oral anticoagulants. - Omeprazole, PPIs: mechanistic-extrapolation concern only; no clinical data. - Covalent-mechanism drugs (clopidogrel, prasugrel, aspirin at antiplatelet dose): theoretical compounding of covalent off-target effects; no clinical signal.

Dose-dependent risk profile: - 50–100 mg/day purified oridonin: tolerated in published TCM and supplement dosing; main risk is sourcing-quality and standardization. - 200–500 mg/day high-dose extracts: case reports of transient ALT elevation; not common but flagged. - Sourcing variability: Rabdosia rubescens whole-extract preparations contain other diterpenoids with unclear safety profiles. Purified oridonin from research chemical suppliers is more characterizable.

Stack interactions: - Synergy with sulforaphane, quercetin (Nrf2 axis): all three are Nrf2 activators; cumulative effect with diminishing returns. - Mechanistic complementarity with BCP, BHB, dapansutrile (CP2): oridonin (Cys279 covalent), BCP (CB2/TLR4), BHB (K+ efflux), dapansutrile (NACHT) all suppress NLRP3 assembly through distinct molecular touch-points — orthogonal additivity expected. - No documented ABCG2 interaction.

(source: supplements-stack.md)

Practical Implementation¶

Sourcing¶

Standardized Rabdosia extract: ~50–100 mg oridonin per dose, easily sourced from supplement suppliers
Isolated oridonin: Higher concentration (95%+ pure), available from specialty suppliers
Cost: Significantly less than pharmaceutical alternatives ($20–40/month for therapeutic dosing)

Dosing¶

Typical range: 50–200 mg oridonin per day (from Rabdosia extract or isolated form)
Timing: With meals; fat may improve absorption
Safety profile: Decades of traditional use at these levels; no known serious adverse effects at therapeutic dosing

Integration with Other Compounds¶

Oridonin + [[bhb-ketones|BHB]] represent a two-pronged NLRP3 inhibition strategy: - Oridonin: direct NLRP3 + Nrf2 activation - BHB: K⁺ efflux blockade + ASC oligomerization prevention - Combined: redundant suppression of multiple inflammasome activation pathways

Oridonin + beta-caryophyllene is a third mechanistically distinct combination worth testing. Oridonin acts covalently at NLRP3 Cys279 (NACHT domain); beta-caryophyllene acts via CB2 agonism upstream (TLR4/MyD88/NF-κB suppression in MSU-stimulated synovium, animal model). No direct combination studies are published, but the mechanisms are non-overlapping, and a combination may allow dose reduction of oridonin — reducing any off-target covalent reactivity risk from chronic dosing. See Cannabinoids & Terpenes for the proposed MSU-model combination experiment. (source: cannabinoids-terpenes.md)

[[nlrp3-inflammasome|NLRP3 Inflammasome]] — The target pathway
[[gout|Gout Flare Cascade]] — The disease mechanism
[[sulforaphane|Sulforaphane and Nrf2 Activation]] — Another Nrf2-activating anti-inflammatory
[[dapansutrile|Dapansutrile]] — Pharmaceutical NLRP3 inhibitor in clinical trials
[[bhb-ketones|Beta-Hydroxybutyrate]] — Complementary NLRP3 mechanism

Key Insight¶

Oridonin bridges traditional medicine and modern immunology. It is a specific, covalent NLRP3 inhibitor with a well-characterized mechanism, available immediately at low cost, with the advantage of centuries of traditional use and the safety history of Rabdosia preparations. Unlike MCC950 (which caused hepatotoxicity) and unlike dapansutrile (which is still in Phase 3), oridonin is available now and targets exactly the same molecular vulnerability (NLRP3 Cys279) that pharmaceutical programs have identified.

The limitation is the absence of gout-specific clinical trials, but the mechanistic case is as strong as it is for any other NLRP3 inhibitor.

Last updated: April 2026 Wiki synthesized from primary research documents